These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 927333)

  • 1. Clinical evaluation of Asaley.
    Bodey GP; Gottlieb JA; Burgess MA; Alexanian R
    Med Pediatr Oncol; 1977; 3(4):365-71. PubMed ID: 927333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZQ therapy in patients with disseminated malignant melanoma.
    Yap BS; Bedikian AY; Burgess MA; Bodey GP
    Am J Clin Oncol; 1982 Dec; 5(6):623-5. PubMed ID: 7165003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
    Sklaroff RB; Casper ES; Magill GB; Young CW
    Cancer Treat Rep; 1980; 64(12):1247-51. PubMed ID: 7471114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptichemio in pretreated patients with ovarian cancer.
    Paccagnella A; Tredese F; Salvagno L; Brandes A; Sileni VC; Daniele O; Fornasiero A; Fosser V; Nicoletto O; Maggino T
    Cancer Treat Rep; 1985 Jan; 69(1):17-20. PubMed ID: 3155650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
    Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
    Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
    Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
    Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.
    Robins HI; Rushing D; Kutz M; Tutsch KD; Tiggelaar CL; Paul D; Spriggs D; Kraemer C; Gillis W; Feierabend C; Arzoomanian RZ; Longo W; Alberti D; d'Oleire F; Qu RP; Wilding G; Stewart JA
    J Clin Oncol; 1997 Jan; 15(1):158-64. PubMed ID: 8996137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
    Cersosimo RJ; Hong WK
    J Clin Oncol; 1986 Mar; 4(3):425-39. PubMed ID: 3005521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
    J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma.
    Leff RS; Thompson JM; Johnson DB; Mosley KR; Daly MB; Knight WA; Ruxer RL; Messerschmidt GL
    J Clin Oncol; 1986 Nov; 4(11):1586-91. PubMed ID: 3534154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas.
    Ajani JA; Dimery I; Chawla SP; Pinnamaneni K; Benjamin RS; Legha SS; Krakoff IH
    Cancer Treat Rep; 1986 Mar; 70(3):375-9. PubMed ID: 3955548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study.
    Thigpen JT; Al-Sarraf M; Hewlett JS
    Cancer Treat Rep; 1979 Apr; 63(4):525-8. PubMed ID: 445506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma.
    Fuks JZ; Van Echo DA; Aisner J; Mitchell EP; Woolley PV; Wiernik PH
    Cancer Clin Trials; 1981; 4(4):411-4. PubMed ID: 7318123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I-II evaluation of cyclocytidine.
    Burgess MA; Bodey GP; Minow RA; Gottlieb JA
    Cancer Treat Rep; 1977; 61(3):437-43. PubMed ID: 68828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients.
    Fornasiero A; Daniele O; Fosser VP; Paccagnella A; Salvagno L; Sileni VC; Morandi P; Fiorentino MV
    Cancer Treat Rep; 1986 May; 70(5):647-9. PubMed ID: 3708613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of spirogermanium given daily.
    Legha SS; Ajani JA; Bodey GP
    J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptichemio in pretreated patients with plasmacell neoplasms.
    Paccagnella A; Salvagno L; Chiarion-Sileni V; Bolzonella S; De Besi P; Frizzarin M; Pappagallo GL; Fosser VP; Fornasiero A; Segati R
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1053-8. PubMed ID: 3780812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of doxifluridine in advanced colorectal adenocarcinoma.
    Abele R; Alberto P; Kaplan S; Siegenthaler P; Hofmann V; Ryssel HJ; Hartmann D; Holdener EE; Cavalli F
    J Clin Oncol; 1983 Dec; 1(12):750-4. PubMed ID: 6230419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.